BridgeBio Pharma (BBIO) News Today $26.49 +0.28 (+1.07%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Geode Capital Management LLC Raises Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Geode Capital Management LLC grew its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 3.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,413,949 shares of the company's stock aftDecember 20 at 4:25 AM | marketbeat.comWellington Management Group LLP Trims Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Wellington Management Group LLP lowered its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 95.3% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 69,586 shares of the company's stock after selling 1,400,524 shares during the quarDecember 19 at 3:33 AM | marketbeat.comPiper Sandler Remains a Buy on BridgeBio Pharma (BBIO)December 18 at 8:21 PM | markets.businessinsider.comOptimistic Buy Rating for BridgeBio Pharma Due to Strong Launch and Strategic InitiativesDecember 18 at 9:52 AM | markets.businessinsider.comBridgeBio Pharma (NASDAQ:BBIO) Earns "Buy" Rating from HC WainwrightDecember 18 at 1:55 AM | americanbankingnews.comBridgeBio Pharma’s Growth Prospects Bolstered by Acoramidis Approval and Promising PipelineDecember 17, 2024 | markets.businessinsider.comHC Wainwright Reiterates Buy Rating for BridgeBio Pharma (NASDAQ:BBIO)HC Wainwright reaffirmed a "buy" rating and issued a $49.00 price objective on shares of BridgeBio Pharma in a research note on Monday.December 16, 2024 | marketbeat.comBarclays PLC Boosts Stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Barclays PLC raised its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 31.9% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 545,008 shares of the company's stock after acquiring an additional 131,743 shares during the period. BarclDecember 16, 2024 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) is Exome Asset Management LLC's 3rd Largest PositionExome Asset Management LLC grew its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 167.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 211,000 shares of the company's stock after acquiring an additiDecember 14, 2024 | marketbeat.comBridgeBio Pharma Announces CHMP's Positive Recommendation Of Acoramidis - Quick FactsDecember 13, 2024 | markets.businessinsider.comAcoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)December 13, 2024 | globenewswire.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Rating of "Moderate Buy" by BrokeragesBridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) has been assigned an average rating of "Moderate Buy" from the fourteen ratings firms that are covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and twelve have issued a bDecember 12, 2024 | marketbeat.comFrazier Life Sciences Management L.P. Has $95.74 Million Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Frazier Life Sciences Management L.P. increased its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 3.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,760,457 shares of the company's stock after purchasingDecember 10, 2024 | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Stock Price Up 8.4% - Should You Buy?BridgeBio Pharma (NASDAQ:BBIO) Trading 8.4% Higher - Should You Buy?December 6, 2024 | marketbeat.comPolar Asset Management Partners Inc. Buys Shares of 50,500 BridgeBio Pharma, Inc. (NASDAQ:BBIO)Polar Asset Management Partners Inc. purchased a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 50,500 shares of the company's stock, valued at approximately $1,December 6, 2024 | marketbeat.comJanus Henderson Group PLC Raises Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Janus Henderson Group PLC increased its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 11.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,818,012 shares of the companyDecember 5, 2024 | marketbeat.comMelqart Asset Management UK Ltd Has $10.27 Million Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Melqart Asset Management UK Ltd increased its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 31.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 403,485 sharesDecember 4, 2024 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Bought by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. grew its position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 8.0% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,284,802 shareDecember 4, 2024 | marketbeat.comUnnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and OncologyDecember 3, 2024 | globenewswire.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Bought by HighVista Strategies LLCHighVista Strategies LLC grew its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 54.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 69,054 shares of the compaDecember 3, 2024 | marketbeat.comErste Asset Management GmbH Buys New Stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Erste Asset Management GmbH bought a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 140,225 shares of the company's stock, valued at approximatelDecember 3, 2024 | marketbeat.comBiotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & MoreNovember 29, 2024 | finance.yahoo.comIntech Investment Management LLC Makes New $1.14 Million Investment in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Intech Investment Management LLC purchased a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 44,623 shares of the company's stocNovember 28, 2024 | marketbeat.comHC Wainwright Analysts Increase Earnings Estimates for BBIOBridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Investment analysts at HC Wainwright lifted their FY2024 earnings per share estimates for shares of BridgeBio Pharma in a research report issued on Monday, November 25th. HC Wainwright analyst R. Selvaraju now expects that the company will earnNovember 27, 2024 | marketbeat.comWhat is Leerink Partnrs' Forecast for BBIO FY2024 Earnings?BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Equities researchers at Leerink Partnrs dropped their FY2024 earnings per share (EPS) estimates for shares of BridgeBio Pharma in a research report issued to clients and investors on Sunday, November 24th. Leerink Partnrs analyst M. Foroohar noNovember 27, 2024 | marketbeat.comBridgeBio Pharma (BBIO) Receives a Hold from OppenheimerNovember 26, 2024 | markets.businessinsider.comBridgeBio Pharma (BBIO) Receives a Buy from Cantor FitzgeraldNovember 26, 2024 | markets.businessinsider.comLeerink Partnrs Expects Weaker Earnings for BridgeBio PharmaBridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Analysts at Leerink Partnrs decreased their FY2027 earnings per share estimates for BridgeBio Pharma in a research report issued on Sunday, November 24th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings perNovember 26, 2024 | marketbeat.comAlgert Global LLC Has $3.47 Million Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Algert Global LLC raised its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 144.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 136,447 shares of the company's stock after purchasing an additionalNovember 26, 2024 | marketbeat.comEagle Asset Management Inc. Decreases Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Eagle Asset Management Inc. decreased its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 95.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,201 shares of the company's stock after sellNovember 26, 2024 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Acquired by Massachusetts Financial Services Co. MAMassachusetts Financial Services Co. MA lifted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 23.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 737,367 shares of the company's stock after purchasing an additional 1November 26, 2024 | marketbeat.comBridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On MondayNovember 25, 2024 | benzinga.comBridgeBio Pharma’s Acoramidis Approval and Competitive Pricing Strategy Boosts Positive Stock OutlookNovember 25, 2024 | markets.businessinsider.comBridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart DrugNovember 25, 2024 | msn.comBridgeBio Stock Hits 2-Month Highs After Analysts Cheer FDA Nod For Heart Drug: Retail Excitement BuildsNovember 25, 2024 | msn.comBridgeBio Pharma (BBIO) Receives a Buy from Piper SandlerNovember 25, 2024 | markets.businessinsider.comBridgeBio Pharma (NASDAQ:BBIO) Shares Gap Up Following Analyst UpgradeBridgeBio Pharma (NASDAQ:BBIO) Shares Gap Up on Analyst UpgradeNovember 25, 2024 | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Given New $45.00 Price Target at Bank of AmericaBank of America raised their target price on shares of BridgeBio Pharma from $42.00 to $45.00 and gave the company a "buy" rating in a research note on Monday.November 25, 2024 | marketbeat.comHC Wainwright Issues Positive Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock PriceHC Wainwright lifted their price objective on shares of BridgeBio Pharma from $43.00 to $49.00 and gave the stock a "buy" rating in a research report on Monday.November 25, 2024 | marketbeat.comBridgeBio: Next Chapter Begins After Attruby ApprovalNovember 24, 2024 | seekingalpha.comJennison Associates LLC Invests $767,000 in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Jennison Associates LLC bought a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 30,119 shares of the company's stock, valued at approxNovember 24, 2024 | marketbeat.comB. Metzler seel. Sohn & Co. Holding AG Purchases New Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 36,603 shares of the company's stock, valNovember 24, 2024 | marketbeat.comBridgeBio Pharma : FDA Approves Heart Disease Drug 'acoramidis'November 23, 2024 | markets.businessinsider.comUS FDA approves BridgeBio's drug for rare heart conditionNovember 22, 2024 | reuters.comAttruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM PatientsNovember 22, 2024 | globenewswire.comBridgeBio Pharma call volume above normal and directionally bullishNovember 21, 2024 | markets.businessinsider.comJ.P. Morgan Keeps Their Buy Rating on BridgeBio Pharma (BBIO)November 21, 2024 | markets.businessinsider.comInsider Selling: BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Sells 4,156 Shares of StockNovember 21, 2024 | insidertrades.comBridgeBio Pharma’s Promising Developments and Undervalued Market Position: A Buy Rating AnalysisNovember 20, 2024 | markets.businessinsider.comBridgeBio Pharma (BBIO) Gets a Buy from ScotiabankNovember 20, 2024 | markets.businessinsider.com Get BridgeBio Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address How Low-Cost Stocks Generate Monthly Income (Ad)Are you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE! 👉 Yes, I Want the Free Report! 👈 BBIO Media Mentions By Week BBIO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BBIO News Sentiment▼0.900.61▲Average Medical News Sentiment BBIO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BBIO Articles This Week▼107▲BBIO Articles Average Week Get BridgeBio Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Teva Pharmaceutical Industries News BeiGene News Moderna News Viatris News Summit Therapeutics News Genmab A/S News Dr. Reddy's Laboratories News Sarepta Therapeutics News Catalent News Vaxcyte News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BBIO) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BBIO Stock Alerts